Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYC overexpression + BCL2 overexpression
i
Other names:
MYC rearrangement-BCL2 rearrangement
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4609
;
596
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
BCL2/BCL2L1 ratio elevation (3)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH1 mutation (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
BCL2/MCL1 ratio elevation (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
BCL2 elevation + IGH elevation (1)
BCL2 fusion + EZH2 mutation (1)
Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)
Chr t(11;14) + BCL2 overexpression (1)
PTEN deletion + BCL2 translocation (1)
BCL2/BAX ratio elevation (0)
BCL2/BCL2L1 ratio elevation (3)
BCL2 rearrangement + MYC amplification (2)
HR positive + MYC amplification (2)
MYC amplification + ALK F1174L (2)
MYC expression + MYC rearrangement (2)
MYC overexpression + IDH1 mutation (2)
MYC overexpression + IDH2 mutation (2)
MYC rearrangement + LDH elevation (2)
BCL2/MCL1 ratio elevation (2)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK positive + MYC amplification + CCND1 deletion (1)
EGFR T790M + MYC amplification (1)
HER-2 positive + MYC amplification (1)
HR positive + MYC mutation (1)
IDH1 mutation + MYC amplification + MAPRE1 overexpression (1)
IDH2 mutation + MYC amplification + MAPRE1 overexpression (1)
KIF5B-RET fusion + TP53 H193R + MYC amplification (1)
MYC amplification + BCL2 amplification + TNFRSF8 expression (1)
MYC mutation + ER positive (1)
miR-17-HG deletion + MYC positive (1)
BCL2 elevation + IGH elevation (1)
BCL2 fusion + EZH2 mutation (1)
Chr t(11;14) + BCL2 : BCL2L1 ratio elevation (1)
Chr t(11;14) + BCL2 overexpression (1)
PTEN deletion + BCL2 translocation (1)
BCL2/BAX ratio elevation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
ibrutinib
Sensitive: B - Late Trials
ibrutinib
Sensitive
:
B
ibrutinib
Sensitive: B - Late Trials
ibrutinib
Sensitive
:
B
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
axicabtagene ciloleucel
Sensitive: C3 – Early Trials
axicabtagene ciloleucel
Sensitive
:
C3
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
Sensitive: C3 – Early Trials
Sensitive
:
C3
Sensitive: C3 – Early Trials
Sensitive
:
C3
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
azacitidine oral
Sensitive: C3 – Early Trials
azacitidine oral
Sensitive
:
C3
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
doxorubicin hydrochloride + chidamide
Sensitive: D – Preclinical
doxorubicin hydrochloride + chidamide
Sensitive
:
D
doxorubicin hydrochloride + chidamide
Sensitive: D – Preclinical
doxorubicin hydrochloride + chidamide
Sensitive
:
D
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
CG-806
Sensitive: D – Preclinical
CG-806
Sensitive
:
D
CG-806
Sensitive: D – Preclinical
CG-806
Sensitive
:
D
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
MYC overexpression + BCL2 overexpression
Diffuse Large B Cell Lymphoma
venetoclax + CG-806
Sensitive: D – Preclinical
venetoclax + CG-806
Sensitive
:
D
venetoclax + CG-806
Sensitive: D – Preclinical
venetoclax + CG-806
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login